Market news

Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026 Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway

GT Biopharma, Inc. (NASDAQ:GTBP) on Tuesday secured IND clearance from the U.S. Food and Drug Administration (FDA) to evaluate its novel therapeutic candidate, GTB-5550, in treating multiple myeloma. Multiple myeloma is a rare type of blood cancer that develops in the plasma cells, which are a type of white blood cell found in the bone marrow. The trial initiation is contingent upon timing and receipt of non-dilutive grant funding. Cash balance as of September 15 is approximately $11 million, an

Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with an update anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins, supporting the anticipation of multi